Changeflow GovPing Pharma & Drug Safety Compositions and Methods for Activating GLP-1 S...
Routine Notice Added Final

Compositions and Methods for Activating GLP-1 Secretion via Nutritional Supplements

Favicon for changeflow.com USPTO Patent Applications - Pharma (A61K)
Published
Detected
Email

Summary

USPTO published patent application US20260096587A1 for nutritional supplement compositions designed to activate GLP-1 peptide secretion to regulate blood sugar, weight, and hunger. The application covers formulations combining hydrolyzed yeast, acacia gum, citrus bioflavonoids, cinnamon bark, MCTs, resistant starches, and botanical extracts, with disclosed efficacy of up to 200% increase in GLP-1 production. Inventors include Elisa Diane Barnes, Christina Beer, Clinton T. Horton, and Robert A. Carr.

What changed

USPTO published patent application US20260096587A1 covering three nutritional supplement compositions for activating GLP-1 hormone secretion. The first composition contains hydrolyzed yeast, acacia gum powder, citrus bioflavonoids, cinnamon bark, and eggplant whole vegetable. The second composition includes medium chain triglycerides, resistant potato starch, resistant tapioca starch, kombucha, guar gum, blueberry juice powder, cranberry fruit powder, and grape seed extract. The third composition combines ingredients from both formulations.

For companies developing metabolic health or weight management supplements, this published application signals competitive IP activity in the GLP-1 activation space using non-pharmaceutical nutritional approaches. Manufacturers should review the specific ingredient combinations and proportions claimed to assess freedom-to-operate for similar product development. The application does not yet constitute granted protection but establishes a priority date for the disclosed formulations.

What to do next

  1. Monitor for patent grant or rejection
  2. Review composition claims for product development freedom
  3. Assess IP landscape for GLP-1 supplement formulations

Archived snapshot

Apr 10, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

COMPOSITIONS AND METHODS FOR ACTIVATING GLP-1 SECRETION

Application US20260096587A1 Kind: A1 Apr 09, 2026

Inventors

Elisa Diane BARNES, Christina Beer, Clinton T. Horton, Robert A. Carr

Abstract

Nutritional supplements and compositions for activating the GLP-1 peptide and/or other hormones in a subject in order to regulate blood sugar, weight, and hunger of the subject are described in this application. The compositions include a first nutritional supplement containing specific amounts of hydrolyzed yeast, acacia gum powder, citrus bioflavonoids, cinnamon bark, and eggplant whole vegetable. The compositions also include a second nutritional supplement containing specific amounts of medium chain triglycerides, resistant potato starch, resistant tapioca starch, kombucha, guar gum, blueberry juice powder, cranberry fruit powder, and grape seed extract. A third composition includes the first and second nutritional supplements containing these ingredients in sufficient amounts to regulate the GLP-1 hormone and/or other hormones. These compositions can increase the total GLP-1 production up to about 200%. Other embodiments are also described.

CPC Classifications

A23L 33/40 A23L 33/30 A61K 31/23 A61K 31/718 A61K 36/06 A61K 36/45 A61K 36/752 A61K 36/87

Filing Date

2025-02-18

Application No.

19056117

View original document →

Get daily alerts for USPTO Patent Applications - Pharma (A61K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.

Last updated

Classification

Agency
USPTO
Published
February 18th, 2025
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US20260096587A1

Who this affects

Applies to
Pharmaceutical companies Manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent application filing Product formulation
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Regulatory Affairs
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!